血管紧张肽转换酶抑制剂和血管紧张肽II受体拮抗剂是临床上已证实的非常有效的抗高血压药物 ,在近年来的研究中发现它们在降压的同时还具有显著的心、肾保护作用 ,并且已有一定数量的临床试验结果显示 ,将 2类药物联合应用可以获得更强大的靶器官保护作用 ,并不会增加不良反应。我们需要更多的大规模临床试验来进一步确证血管紧张肽转换酶抑制剂和血管紧张肽II受体拮抗剂联合用药在这方面的有效性和安全性 ,使心、肾功能不全及有蛋白尿的病人获得最有益的治疗。 Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists are clinically proven very effective antihypertensive drugs, in recent studies have found that they also have significant antihypertensive heart and kidney Protection, and a number of clinical trials have shown that the combination of two types of drugs can be more powerful target organ protection, and does not increase the adverse reactions. We need more large-scale clinical trials to further confirm the combination of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in this regard the effectiveness and safety of the heart and kidney dysfunction and proteinuria Of patients receive the most beneficial treatment.